Introducing Andelyn's AAV Curator™ Modular and Configurable AAV Gene Therapy Manufacturing Platform
Andelyn's Chief Commercial Officer, Matt Niloff, presents Andelyn's platform approach to AAV gene therapy manufacturing. The Andelyn AAV Curator™ platform is built on configurability, ensuring the end process is curated to each client program’s specific needs. Presented in the May 2024 Outsourced Pharma Capacity Update program, the presentation contains an overview of Andelyn and the platform, as well as information about the AAV Curator™ Cell Line, Key Considerations in platform choices, the Optimization-By-Design™ methodology that powers the platform's successful implementation, elements of Cost of Goods Reduction, and the benefits of Full Program Partnering with Andelyn Biosciences, a gene therapy CDMO with 20 years' experience in GMP AAV manufacturing.
Andelyn's Chief Commercial Officer, Matt Niloff, presents Andelyn's platform approach to AAV gene therapy manufacturing. The Andelyn AAV Curator™ platform is built on configurability, ensuring the end process is curated to each client program’s specific needs. Presented in the May 2024 Outsourced Pharma Capacity Update program, the presentation contains an overview of Andelyn and the platform, as well as information about the AAV Curator™ Cell Line, Key Considerations in platform choices, the Optimization-By-Design™ methodology that powers the platform's successful implementation, elements of Cost of Goods Reduction, and the benefits of Full Program Partnering with Andelyn Biosciences, a gene therapy CDMO with 20 years' experience in GMP AAV manufacturing.
Andelyn's Chief Commercial Officer, Matt Niloff, presents Andelyn's platform approach to AAV gene therapy manufacturing. The Andelyn AAV Curator™ platform is built on configurability, ensuring the end process is curated to each client program’s specific needs. Presented in the May 2024 Outsourced Pharma Capacity Update program, the presentation contains an overview of Andelyn and the platform, as well as information about the AAV Curator™ Cell Line, Key Considerations in platform choices, the Optimization-By-Design™ methodology that powers the platform's successful implementation, elements of Cost of Goods Reduction, and the benefits of Full Program Partnering with Andelyn Biosciences, a gene therapy CDMO with 20 years' experience in GMP AAV manufacturing.